Alendronate Regulates Knee Arthritis by Extracellular-Signal-Regulated Kinase (ERK) Pathway in Rat Model
The incidence of knee arthritis is high and treatment effect is not satisfactory. Alendronate (ALN) can treat metabolic bone diseases. But its role and mechanism in knee arthritis remains unclear. SD rats were randomly assigned into control group; model group; and alendronate group followed by analysis of the pathological changes by HE staining and Masson staining, bone mineral density by dual energy bone densitometry, expression of glycosaminoglycan and MMP-3 by immunohistochemistry, BMP-2 and BMP-4 expression by Real time PCR, IL-1β, IL-6 secretion by ELISA as well as ERK signaling protein level by Western blot. In model group, the pathological changes of joint inflammation were obvious with fibrosis on the cartilage surface, significantly increased synovial hyperplasia score, inflammatory infiltration score and Mankin score, decreased bone density, expression of glycosaminoglycan, MMP-3, BMP-2 and BMP-4 as well as increased IL-1β, IL-6 secretion and ERK1/2 expression (P <0.05). Alendronate treatment can significantly improve joint inflammation, reduce inflammatory infiltration score and Mankin score, increase bone density, expression of glycosaminoglycan, MMP-3, BMP-2 and BMP-4, decrease the secretion of IL-1β, IL-6 and expression of ERK1/2 in a rat model of knee arthritis (P <0.05). Alendronate can promote glycosaminoglycans and MMP-3 expression, and synthesis of BMP-2 and BMP-4 by inhibiting ERK pathway, inhibiting the secretion of inflammatory factors, thus ameliorating knee arthritis.